Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL

Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. The L-MIND (NCT02399085) trial, an open-label, single-arm, phase II study of Tafasitamab (TAFA) plus lenalidomide (LEN), reported progression-free survival of 16 months in R/R DLBCL patients ineligible for auto...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabbara, Nadeem, Gaut, Daria, Oliai, Caspian, Lewis, Tara, de Vos, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322434/
https://www.ncbi.nlm.nih.gov/pubmed/34354920
http://dx.doi.org/10.1016/j.lrr.2021.100260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322434/
https://www.ncbi.nlm.nih.gov/pubmed/34354920
http://dx.doi.org/10.1016/j.lrr.2021.100260

Ejemplares similares